Who is eligible for clinical trial NCT05998135?

Participants must meet protocol criteria for Ovarian High Grade Serous Adenocarcinoma. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05998135 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2025-09-05

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer (NCT05998135)

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Emory University

🩺 Plain-English Summary (8th-Grade Level)

This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (5 items) and avoid the listed exclusions (5 items).

Location: Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy
Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
There will be no limitations on number of prior lines of therapy
Trial is open to non-English speaking patients
Trial is open to patients referred from community practice

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Patients who are \< 18 years old
Patients who are pregnant or breastfeeding (due to cancer of their reproductive organs, patients enrolled in the trial are unable to conceive)
Patients who are incarcerated
Patients who are unable to provide consent / lack decision-making capacity

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗